胃黏膜肠上皮化生的规范化内镜诊断和长期随访

注册号:

Registration number:

ChiCTR1900021805 

最近更新日期:

Date of Last Refreshed on:

2019-03-11 09:09:02 

注册时间:

Date of Registration:

2019-03-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

胃黏膜肠上皮化生的规范化内镜诊断和长期随访

Public title:

The normalized endoscopic diagnosis and long-term follow-up of gastric intestinal metaplasia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

胃黏膜肠上皮化生的规范化内镜诊断和长期随访

Scientific title:

The normalized endoscopic diagnosis and long-term follow-up of gastric intestinal metaplasia

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

冉涛 

研究负责人:

杨朝霞 

Applicant:

Tao Ran 

Study leader:

Zhaoxia Yang 

申请注册联系人电话:

Applicant telephone:

+86 13896840797

研究负责人电话:

Study leader's
telephone:

+86 13637896168

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

rantao@stu.cqmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

414229152@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区临江路76号

研究负责人通讯地址:

重庆市渝中区临江路76号

Applicant address:

76 Linjiang Road, Yuzhong District, Chongqing, China

Study leader's address:

76 Linjiang Road, Yuzhong District, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

400010

研究负责人邮政编码:

Study leader's postcode:

400010

申请人所在单位:

重庆医科大学附属第二医院

Applicant's institution:

The Second Affiliated Hospital of Chongqing Medical University

研究负责人所在单位:

重庆医科大学附属第二医院

Affiliation of the Leader:

The Second Affiliated Hospital of Chongqing Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

9

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属第二医院伦理委员会

Name of the ethic committee:

The Ethics Committee of The Second Affiliated Hospital of Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2019-02-27 00:00:00

伦理委员会联系人:

王大刚

Contact Name of the ethic committee:

dagang wang

伦理委员会联系地址:

重庆市渝中区临江门76号

Contact Address of the ethic committee:

76 Linjiang Road, Yuzhong District, Chongqing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 023 63693014

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆医科大学附属第二医院

Primary sponsor:

The Second Affiliated Hospital of Chongqing Medical University

研究实施负责(组长)单位地址:

重庆市渝中区临江门76号

Primary sponsor's address:

76 Linjiang Road, Yuzhong District, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第二医院

具体地址:

重庆市渝中区临江门76号

Institution
hospital:

The Second Affiliated Hospital of Chongqing Medical University

Address:

76 Linjiang Road, Yuzhong District, Chongqing, China

经费或物资来源:

重庆市卫生计生委医学科研项目

Source(s) of funding:

Medical Research Projects of Chongqing Health and Family Planning Commission

研究疾病:

胃黏膜肠上皮化生  

Target disease:

Gastric Intestinal Metaplasia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

寻找诊断肠化的最佳内镜方法; 针对肠化患者制定合适的随访计划; 比较不同药物治疗肠化的效果。  

Objectives of Study:

Find a properer endoscopic method to diagnose intestinal metaplasia; Develop appropriate follow-up plans for patients with intestinal metaplasia; Compare the effects of different drugs on intestinal metaplasia.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

(1)心肺功能不全、脑卒中、明显胸腹动脉瘤或处于休克昏迷等不能耐受检查者;
(2)疑有消化道出血、穿孔、腹膜炎、腹水、严重腹胀者;
(3)颈椎外伤,脊柱畸形者;
(4)有出血性疾病(包括凝血功能异常)者;
(5)阿片类药物或催眠药物成瘾与依赖及长期嗜酒者;
(6)无法沟通、有神经精神系统疾病或无法配合者;
(7)上消化道腐蚀性炎症;
(8)孕妇或正处于哺乳期;
(9)有麻醉药物过敏史或过敏体质者;
(10)其他研究者讨论认为不能参加本研究的情况。

Exclusion criteria:

1. Cardiopulmonary insufficiency, stroke, obvious thoracoabdominal aneurysm or be in a coma;
2. Suspected gastrointestinal bleeding, perforation, peritonitis , ascites, severe bloating;
3. Spine deformity;
4. Bleeding disorders (including coagulation disorders);
5. Opioid,alcohol or hypnotic addiction and dependence;
6. Unable to communicate, serious neuropsychiatric diseases or unable to cooperate;
7. Upper gastrointestinal corrosive inflammation;
8. Pregnant women or in the process of breastfeeding;
9. Allergic history of the drugs that would be used;
10. Other situation that they can't participate in this study.

研究实施时间:

Study execute time:

From 2019-03-11 00:00:00 To 2023-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-03-11 00:00:00 To 2019-12-31 00:00:00

干预措施:

Interventions:

组别:

Hp(-) group 1

样本量:

20

Group:

Hp(-) group 1

Sample size:

干预措施:

安慰剂

干预措施代码:

Intervention:

placebo

Intervention code:

组别:

Hp(+) group 3

样本量:

20

Group:

Hp(+) group 3

Sample size:

干预措施:

叶酸

干预措施代码:

Intervention:

folic acid

Intervention code:

组别:

Hp(+) group 2

样本量:

20

Group:

Hp(+) group 2

Sample size:

干预措施:

羔羊胃提取物

干预措施代码:

Intervention:

Extracts from Animal Gastric

Intervention code:

组别:

Hp(+) group 1

样本量:

20

Group:

Hp(+) group 1

Sample size:

干预措施:

叶酸及羔羊胃提取物联合治疗

干预措施代码:

Intervention:

Combined treatment(Extracts from Animal Gastric and folic acid)

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第二医院 

单位级别:

三甲医院 

Institution
hospital:

The Second Affiliated Hospital of Chongqing Medical University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

肠上皮化生

指标类型:

主要指标

Outcome:

Diagnosis of intestinal metaplasia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肠上皮化生是否逆转

指标类型:

主要指标

Outcome:

Whether intestinal metaplasia is reversed

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胃黏膜萎缩情况

指标类型:

主要指标

Outcome:

Atrophy of gastric mucosa

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

黏膜

组织:

Sample Name:

mucosa

Tissue:

gastric

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 14 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

分层区组随机化

Randomization Procedure (please state who generates the random number sequence and by what method):

stratifed block randomization

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

原始数据于试验结束后6个月以内采用ResMan临床试验公共管理平台向公众开放查询,网址:www.medresman.org.

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The raw data will be open to the public with ResMan in the 6 months after clinical trials finished,Website: www.medresman.org.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

所有数据录入Excel表格中

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All of the data will be kept in several Excel forms.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-03-11 09:09:02